PharmaShots | Incisive News in 3 Shots

Subscribe Now

HER2-positive Breast Cancer

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

March 25, 2021

Roche's Phesgo (Perjeta + Herceptin) Receives EC's Approval for the Treatment of HER2-Positive Breast Cancer

Roche's Phesgo (Perjeta + Herceptin) Receives EC's Approval for the Treatment of HER2-Positive Breast Cancer

December 23, 2020

MacroGenics' Margenza (margetuximab-cmkb) Receives the US FDA's Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MacroGenics' Margenza (margetuximab-cmkb) Receives the US FDA's Patients with Pretreated Metastatic HER2-Positive Breast Cancer

December 15, 2020

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

Roche Reports Results of Perjeta (pertuzumab) Fixed Dose SC Combination Therapy in P-III FeDeriCa Study for HER2+ve Breast Cancer

September 13, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us